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The role of androgens in cardiovascular disease 
(CVD) remains controversial. Although men de-
velop CVD earlier than women, consistent with 
increased atherosclerosis (Wingard et al., 1983; 
Shaw et al., 2006), repair/adaptation mecha-
nisms may be enhanced in males (Joseph and 
Dyson, 1965). For example, male sex is associ-
ated with increased collateralization in patients 
with severe coronary artery lesions (Abaci et al., 
1999). Androgens have been implicated in play-
ing a detrimental role in CVD by numerous in 
vitro studies (McCrohon et al., 1999; Ng et al., 
2003a,b), but in vivo and clinical studies fail to 
support this relationship (Liu et al., 2003; Wu 
and von Eckardstein, 2003; Harman, 2005). 
Indeed, some but not all cohort studies suggest 
that subnormal blood levels of testosterone are 
deleterious and correlate with increased cardio-
vascular risk factors and mortality (Araujo et al., 
2007; Khaw et al., 2007; Laughlin et al., 2008; 
Tivesten et al., 2009).
Angiogenesis is a prerequisite for embryonic 
development and plays a critical role in adult 
physiological processes such as wound repair 
and in tissue responses to ischemia (Carmeliet, 
2005). The cardiovascular system is an important 
target of androgen action (Liu et al., 2003), and 
although the effect of estrogen in angiogenesis 
has been studied extensively (Losordo and Isner, 
2001), the role of androgens in this process 
remains largely unexplored.
Androgens have been implicated in the re-
newal of various tissues, including muscle and 
bone (Harman, 2005), but their potential role 
in  the  maintenance  of  cardiovascular  repair 
mechanisms is unknown. As androgens have been 
implicated in the regulation of angiogenesis-
related genes (Ng et al., 2003b; Death et al., 
2004), we reasoned that androgens may play a 
role in angiogenesis, a process critical in the re-
generative response after ischemia. To examine 
the role of androgens in angiogenesis, we used 
dihydrotestosterone (DHT), the most potent 
natural androgen that acts via the androgen   
receptor (AR). As testosterone action partly   
depends on its conversion to estradiol by the 
unique enzyme CYP19 (aromatase), whereas 
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Mounting evidence suggests that in men, serum levels of testosterone are negatively cor-
related to cardiovascular and all-cause mortality. We studied the role of androgens in 
angiogenesis, a process critical in cardiovascular repair/regeneration, in males and females. 
Androgen exposure augmented key angiogenic events in vitro. Strikingly, this occurred in 
male but not female endothelial cells (ECs). Androgen receptor (AR) antagonism or gene 
knockdown abrogated these effects in male ECs. Overexpression of AR in female ECs con-
ferred androgen sensitivity with respect to angiogenesis. In vivo, castration dramatically 
reduced neovascularization of Matrigel plugs. Androgen treatment fully reversed this effect 
in male mice but had no effect in female mice. Furthermore, orchidectomy impaired blood-
flow recovery from hindlimb ischemia, a finding rescued by androgen treatment. Our find-
ings suggest that endogenous androgens modulate angiogenesis in a sex-dependent 
manner, with implications for the role of androgen replacement in men.
© 2010 Sieveking et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Chronic exposure to DHT (72 h) induced a dose-dependent 
increase in male EC tubulogenesis (Fig. 1, D and E), as did 24 h 
of exposure (Fig. S1). Similarly, DHT augmented male EC 
proliferation in a dose-dependent fashion after 48 h (Fig. 1 F). 
Again, addition of HF abolished all androgen-mediated ef-
fects on these key angiogenic events, consistent with an AR-
dependent mechanism (Fig. 1, B, C, E, and F).
As an independent method to verify the pivotal involve-
ment of AR in DHT-mediated angiogenic effects, we also 
assessed tubulogenesis in male ECs subjected to small inter-
fering RNA (siRNA)–mediated knockdown of AR. DHT 
effects were also abolished in ECs exposed to AR siRNA (Fig. 
1 G). DHT can also mediate effects via direct cross-reactivity 
at the ER at sufficiently high concentrations. Therefore, to 
further exclude any contribution to DHT effects via effects 
on ERs, we assessed tubulogenesis in male ECs treated with 
the highest concentration of DHT with or without the ER 
antagonist ICI182780. The addition of ICI182780 did not 
have any effect on DHT-mediated augmentation of tubulo-
genesis (Fig. 1 H). These findings are consistent with an AR-
mediated angiogenic effect in male ECs.
Androgens do not augment angiogenic events in vitro  
in female ECs
Mounting evidence indicates that sex steroids regulate vari-
ous vascular biological processes in a sex-dependent fashion 
DHT cannot be aromatized, the use of DHT avoids the 
potentially  confounding  estrogen  receptor  (ER)–mediated 
effects of testosterone.
RESULTS AND DISCUSSION
Androgens augment angiogenic events in vitro  
in male endothelial cells (ECs)
Male ECs treated with DHT demonstrated a dose-dependent 
increase in key angiogenic processes in vitro (Fig. 1). EC mi-
gration was assessed by two different methods. Cells were pre-
treated with varying doses of DHT (0, 4, 40, and 400 nM) and 
subsequently  assessed  using  a  Boyden  chamber  assay  or  a 
scratch wounding assay. Using the Boyden chamber assay, 24 h 
of  DHT  administration  induced  dose-dependent  male  EC 
migration (220 ± 22, 262 ± 38, and 336 ± 39% vs. 100% con-
trol value for DHT at 4, 40, and 400 nM, respectively; P < 
0.001 using analysis of variance [ANOVA]; Fig. 1 B). Similar 
results were obtained using a scratch wounding assay. Migra-
tion by male ECs was augmented in a dose-dependent fashion 
(138 ± 7, 280 ± 23, and 306 ± 32%; P < 0.01 using ANOVA; 
Fig. 1 C). Interestingly, in both assays, addition of the AR 
antagonist hydroxyflutamide (HF) abrogated DHT-mediated 
EC migration (96 ± 6 and 94 ± 6% vs. 100% control value for 
40 and 400 nM DHT + HF, respectively; P > 0.05; Fig. 1,   
B and C). DHT effects on tubulogenesis were assessed using 
both Matrigel and co-culture methods (Sieveking et al., 2008). 
Figure 1.  DHT augments key angiogenic events in vitro in male ECs via the AR. (A and B) Boyden chamber (cells were stained with Ulex lectin 
[UEA-1] and DAPI) and (C) scratch wounding assays of migration by male ECs pretreated with DHT or vehicle (0.1% EtOH) for 24 h ± HF, assessed after 6 
and 24 h, respectively. Bar, 50 µm. (D and E) Vascular network formation by male ECs exposed to DHT or vehicle ± HF for 72 h. Tubule area was quantified 
using image analysis software (ImageJ; available at http://rsbweb.nih.gov/ij/). Bar, 100 µm. (F) Proliferation of male ECs exposed to DHT or vehicle ± HF for 
24 h, assessed by direct cell counting (n = 4 independent experiments for A–F, respectively). (G and H) Matrigel assays of male ECs transfected with siRNA 
targeted to the AR (G) or pretreated with the ER blocker ICI182780 and treated with DHT (H; n = 3 independent experiments). **, P < 0.01; and ***, P < 
0.001 versus control using ANOVA. All data are expressed as means ± SEM. For each independent experiment, cells from a different donor were used.JEM VOL. 207, February 15, 2010  347
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for 0, 4, 40, and 400 nM DHT, respectively; P = 0.0024; 
Fig. 3 A). Similarly, DHT induced dose-dependent increases 
in the messenger RNA (mRNA) expression of VEGF re-
ceptors 1 and 2 (Flt-1 and KDR, respectively; Fig. 3, B and C). 
However, flow cytometric assessment of surface VEGF recep-
tor levels revealed that DHT augmented KDR but not Flt-1 
expression in a dose-dependent manner (Fig. 3, D and E). As 
KDR is the chief mediator of the mitogenic/angiogenic action 
of VEGF in ECs, whereas Flt-1 may function as a negative 
regulator of VEGF action (Ferrara et al., 2003), our findings 
are consistent with a proangiogenic role for DHT through 
VEGF signaling via KDR. Furthermore, the addition of anti-
VEGF antibody abrogated DHT-mediated increases in tubu-
logenesis (Fig. 3 F). Likewise, LY294002, an inhibitor of 
phosphoinositol 3-kinase (PI3K), a key enzyme in the PI3K–
AKT pathway of VEGF signaling, inhibited DHT-mediated 
tubulogenesis (Fig. 3 F). These findings suggest that the proan-
giogenic effects of DHT in male ECs are VEGF dependent.
Endogenous androgens are necessary for angiogenesis  
in vivo in males but not females
Having demonstrated a sex-specific role for androgens in 
angiogenesis in vitro, we next assessed the role of androgens 
in angiogenesis in vivo, first using a Matrigel plug implanta-
tion model. Sexually mature male and female mice under-
went gonadectomy or a sham gonadectomy followed by 
DHT  administration.  Orchidectomy  markedly  decreased 
in vivo vascularization of Matrigel plugs (27.3 ± 2% mm2 
von Willebrand factor [vWF]+ cells/mm2 Matrigel vs. con-
trol as 100%; P < 0.0001 using ANOVA; Fig. 4 A). As can 
be observed in the representative image, these plugs were 
virtually acellular. Androgen treatment fully reversed the cas-
tration-related impairment of angiogenesis in males, returning 
  (McCrohon et al., 1999; Ng et al., 2001; Ng et al., 2003b). 
For androgens, this is related to an approximately two- to 
fourfold increased AR expression in male vascular cells com-
pared with females (McCrohon et al., 2000; Death et al., 
2004).  We  therefore  hypothesized  that  the  proangiogenic 
effects of DHT observed in ECs may also be sex dependent. 
Unlike male ECs, exposure of female ECs to DHT had no 
effect on migration (Fig. 2, A and B), tubulogenesis (Fig. 2 C), 
or proliferation (P > 0.05; Fig. 2 D), consistent with andro-
gen-mediated sex-specific effects. To further examine the 
role of the AR in mediating the sex-dependent effects of 
DHT on angiogenesis, we overexpressed the AR in female 
ECs (Fig. S2) and assessed tubulogenesis after exposure to 
DHT. Female ECs overexpressing the AR became respon-
sive to DHT and displayed augmented tubulogenesis (114 ± 
6% vs. 100% control value; P < 0.05 using the Student’s   
t test), albeit to a lesser extent than in male cells (Fig. 2 E). 
These findings indicate that the sex-specific effects of DHT 
on angiogenesis are at least in part mediated by sex differ-
ences in AR expression. As there are a variety of coregulators 
involved in AR signaling (Liu et al., 2003), it is also possible 
that many of these are also expressed in a sex-specific fashion 
and are important for androgenic modulation of angiogenesis.
The proangiogenic effect of androgens in vitro are vascular 
endothelial growth factor (VEGF) dependent
Next, to further elucidate the means by which DHT aug-
mented migration, proliferation, and tubulogenesis in male 
ECs, cells exposed to DHT were assessed for the expression of 
various proangiogenic factors. Exposure of male ECs to DHT 
produced  a  dose-dependent  increase  in  the  production  of 
VEGF, a key angiogenic growth factor (102.8 ± 7, 107.8 ± 7, 
118.9 ± 6, and 147.2 ± 15 pg VEGF/100 µg of cell protein 
Figure 2.  DHT does not augment key angiogenic events in vitro in female ECs. (A–D) Boyden chamber (A) and scratch wounding (B) assays of 
migration assessed after 6 and 24 h, respectively, Matrigel assays (C), and proliferation by female ECs treated with DHT or vehicle (D; n = 4 indepen-
dent experiments). P > 0.05 using ANOVA. (E) Matrigel assays of female ECs transfected with an AR overexpression plasmid and treated with DHT (n = 
3 independent experiments). *, P < 0.05 using the Student’s t test. All data are expressed as means ± SEM. For each independent experiment, cells from 
a different donor were used.348 Androgens and angiogenesis | Sieveking et al.
detectable as early as day 3 and significant by day 5 after isch-
emia (LDPI at day 5 after ischemia: control, 0.28 ± 0.04; or-
chidectomized + DHT, 0.4 ± 0.05; P < 0.05 vs. orchidectomized 
mice; Fig. 5 A). These findings were also borne out in the 
functional assessments of recovery (Fig. S3). The serial changes 
in perfusion observed after femoral artery ligation have previ-
ously been shown to correlate with changes in vessel density 
as determined by histological analysis (Couffinhal et al., 
1998). As early as day 7, immunohistochemical staining of 
the adductor muscles of the ischemic hindlimbs revealed that 
capillary density was impaired in orchidectomized mice and 
augmented in DHT-treated orchidectomized mice (0.17 ± 
0.01 and 0.27 ± 0.01 vs. 0.22 ± 0.01 capillaries/myofiber for 
orchidectomized mice, orchidectomized + DHT mice, and 
controls, respectively; P < 0.001 using ANOVA; Fig. 5, B 
and C), consistent with the findings observed for limb perfu-
sion. Mean vessel diameter was also significantly smaller in 
orchidectomized mice (P < 0.001; Fig. 5 D). Interestingly, 
mean vessel diameter was also smaller in orchidectomized 
mice receiving DHT, but DHT treatment appeared to miti-
gate the effects of castration. These data suggest that, in the 
context of ischemia, endogenous androgens influence the 
rate and extent of ischemia-induced angiogenesis and play a 
role in arteriogenesis.
To elucidate the mechanisms of androgen-induced angio-
genesis in the context of hindlimb ischemia, we assessed the 
early expression of angiogenesis- and ischemia-related genes. 
Notably, 3 d after ischemia, orchidectomy significantly re-
duced the expression of hypoxia-inducible factor 1 (HIF-1; 
0.5 ± 0.1 vs. 1.8 ± 0.2 relative mRNA expression ischemic/
nonischemic for orchidectomized mice vs. controls, respec-
tively; P < 0.05 using ANOVA) and stromal cell–derived 
factor 1 (SDF-1; 0.7 ± 0.1 vs. 2.4 ± 0.1 relative mRNA 
vascularization of Matrigel plugs to levels not significantly 
different to controls (91 ± 6% mm2 vWF+ cells/mm2 Matri-
gel vs. control as 100%; P < 0.001).
Consistent with previous findings, ovariectomy attenuated 
Matrigel plug vascularization in females (Morales et al., 1995), 
albeit to levels more modest than in males (53 ± 8% mm2 
vWF+ cells/mm2 Matrigel vs. control as 100%; P < 0.0001 us-
ing ANOVA; Fig. 4 B). In striking contrast to their male coun-
terparts, gonadectomy-related impairment of angiogenesis in 
females was not reversed by DHT treatment (55 ± 6% vs. con-
trol as 100%; P < 0.0001 using ANOVA). In accordance with 
our in vitro findings, these data suggest that endogenous andro-
gens play a role in angiogenesis in males but not females.
Endogenous androgens modulate  
ischemia-induced angiogenesis
Hypoxia is one of the most potent angiogenic stimuli (Ceradini 
and Gurtner, 2005). To investigate the role of androgens in 
ischemia-induced angiogenesis, we used a mouse model of 
hindlimb ischemia involving the unilateral ligation and re-
moval of the femoral artery (Couffinhal et al., 1998). Male 
mice were randomized to orchidectomy with or without 
DHT treatment or a sham orchidectomy. Laser Doppler per-
fusion imaging demonstrated that orchidectomy markedly 
inhibited the rate of recovery from hindlimb ischemia (laser 
Doppler perfusion index [LDPI] ischemic/nonischemic ratio 
after 11 d: control, 0.54 ± 0.04; castrate, 0.39 ± 0.04; P < 
0.05; Fig. 5 A). In functional assessments of the ischemic 
hindlimbs, orchidectomized animals also displayed impaired 
recovery in foot movement and ischemic damage (Fig. S3). 
Interestingly,  DHT  not  only  rescued  the  orchidectomy-
  induced impairment of blood flow recovery but also enhan-
ced recovery from ischemia, with improvements in flow 
Figure 3.  Proangiogenic effects of DHT in male ECs is VEGF dependent. (A) Production of VEGF by male ECs exposed to DHT for 48 h. Total cell 
lysate protein was quantified and assayed via ELISA (n = 4 independent experiments). P = 0.002 using ANOVA for linear trend. (B) Expression of Flt-1  
(P = 0.0128) and (C) KDR (P = 0.0295) mRNA and (D) Flt-1 and (E) KDR (P = 0.0005) protein in male ECs exposed to DHT for 48 h (using ANOVA for linear 
trend). (F) Vascular network formation in male ECs treated with DHT with and without 1 µg/ml anti-VEGF antibody or 10 µM of the PI3K inhibitor 
LY294002 (n = 3 independent experiments for B–F, respectively). ***, P < 0.001 compared with control using ANOVA. All data are expressed as means ± 
SEM. For each independent experiment, cells from a different donor were used.JEM VOL. 207, February 15, 2010  349
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DHT, the increases observed for SDF-1 and KDR in DHT-
treated mice are also related to induction of HIF-1 (Ceradini 
et al., 2004). There were trends toward a reduction in VEGF 
expression in orchidectomized animals and an increase with 
DHT treatment that were not statistically significant. Never-
theless, given the critical role of HIF-1 in inducing VEGF-
related angiogenic events in ischemia and an increased expression 
of KDR, our in vivo findings are compatible with a role for 
expression ischemic/nonischemic for orchidectomized mice 
vs. controls, respectively; P < 0.05 using ANOVA), which are 
key factors in the coordination of angiogenic gene expres-
sion and progenitor cell migration and homing, respectively 
(Fig. 5, E and F, respectively; Ceradini et al., 2004). In stark 
contrast, DHT treatment of orchidectomized mice augmented 
expression of HIF-1 (3 ± 0.8; P < 0.01) and SDF-1 (3.6 ± 
0.9; P < 0.01). These mice also demonstrated increased ex-
pression of KDR (3 ± 0.8 vs. 0.6 for orchidectomized + DHT 
vs. controls, respectively; P < 0.01 using ANOVA; Fig. 5 G), 
providing support for a role of DHT in VEGF signaling in 
vivo. Furthermore, similar trends were observed for VEGF and 
neuropillin-1 (Fig. S4). HIF-1 is the key subunit to HIF-1, 
which is a critical, genome-wide transcription regulator re-
sponsible for oxygen homeostasis and responsive to hypoxic 
stress (Semenza, 2002; Ceradini and Gurtner, 2005). It drives 
the expression of >100 genes, including key genes associated 
with angiogenesis such as VEGF and its receptors (Semenza, 
2002). It is noteworthy that androgens have been associated 
with HIF-1 expression in the prostate (Boddy et al., 2005). 
Hence, it is possible that in addition to the direct effects of 
Figure 4.  Endogenous androgens play a role in angiogenesis in 
males but not females. (A) Vascularization of Matrigel plugs harvested 
from male mice after 14 d, with representative images (n = 8/group; 
combined data from four independent experiments are shown). Sections 
were immunohistochemically stained for vWF (3,3-diaminobenzidine 
[DAB] + nickel, eosin). Bars, 100 µm. (B) Vascularization of Matrigel plugs 
harvested from female mice, with representative images (n = 5–6/group; 
combined data from three independent experiments are shown). Sections 
were immunohistochemically stained for vWF (DAB, hematoxylin). Bars, 
50 µm. ***, P < 0.001 versus control using ANOVA. All data are expressed 
as means ± SEM.
Figure 5.  Endogenous androgens modulate ischemia-induced an-
giogenesis. (A) LDPI. Limb perfusion ratio (ischemic/nonischemic) is pre-
sented with representative images (n = 8/group; combined data from four 
independent experiments are shown). Differences between groups were 
assessed by two-way ANOVA with Bonferroni correction (brackets at 
right). *, P < 0.05; and **, P < 0.01 for comparisons between orchidecto-
mized and orchidectomized + DHT mice at individual time points. (B) Rep-
resentative images of neovascularization of ischemic hindlimbs at day 7. 
Capillary density was measured in 8-µm frozen sections of the adductor 
muscles via immunohistochemical staining for vWF (arrows). Bars, 100 µm. 
(C) Capillary density expressed as the number of capillaries per myofiber 
(eosin) and (D) mean vessel diameter (n = 6/group; combined data from 
three independent experiments are shown). (E–G) Mechanisms of andro-
genic modulation of angiogenesis in hindlimb ischemia at day 3. Quantita-
tive RT-PCR for the expression of the angiogenesis- and ischemia-related 
genes (E) HIF-1, (F) SDF-1, and (G) KDR (n = 6/group; combined data 
from three independent experiments are shown). *, P < 0.05; **, P < 0.01; 
and ***, P < 0.001 versus control using ANOVA. All data are expressed as 
means ± SEM.350 Androgens and angiogenesis | Sieveking et al.
  castration-mediated decline in ulex+/AcLDL+ angiogenic cells 
in both the spleen (17.8 ± 0.9 cells/200× field; P > 0.05 using 
ANOVA) and the bone marrow (31.7 ± 5 cells/200× field; 
P < 0.001 using ANOVA). SDF-1 is a key chemokine in the 
migration and homing of bone marrow–derived progenitor 
cells to sites of ischemia, and is itself a ligand for the receptor 
CXCR4 (Jin et al., 2006); therefore, we also assessed the levels 
of CXCR4+/Sca-1+ progenitor cells after induction of hindlimb 
ischemia. Consistent with increased expression of SDF-1, 
orchidectomized mice receiving DHT had significantly ele-
vated numbers of CXCR4+/Sca-1+ cells present in the bone 
marrow at day 3 after ischemia (0.8 ± 0.2% vs. 0.4 ± 0.07% of 
MNCs for orchidectomized + DHT vs. controls, respectively; 
P < 0.05 using ANOVA; Fig. 6 C). Trends similar to those 
seen for ulex+/AcLDL+ cells were observed in the spleen for 
CXCR4+/Sca-1+ cells (i.e., decrease with castration and increase 
with DHT treatment), but these were not statistically signifi-
cant (Fig. 6 D). The mobilization of cells from the bone mar-
row to the periphery is a highly coordinated, time-dependent 
event. Therefore, because sampling took place at day 3, it is 
possible  that  the  significantly  elevated  numbers  of  Sca-1+/
CXCR4+ cells in the bone marrow would not correspond to 
higher levels in the periphery until a later time point. Overall, 
our findings suggest that androgens play a role in the prolifera-
tion and mobilization of circulating angiogenic cell populations 
in the context of ischemia.
Finally, in light of the well-established effects of andro-
gens on erythropoiesis (Kennedy and Gilbertsen, 1957), we 
assessed erythroid progenitor cell levels, as these cells have 
been demonstrated to augment angiogenesis (Sasaki et al., 
2007). Gonadal status had no effect on the numbers of gran-
ulocyte/macrophage progenitors present in the bone mar-
row or the spleen (Fig. 6, E and F). However, consistent 
VEGF in this context. Overall, these findings suggest that 
endogenous androgens play a role in the coordination of 
ischemia-mediated  angiogenesis  by  the  regulation  of  key 
angiogenesis-related genes, including HIF-1 and SDF-1.
Androgens modulate ischemia-induced  
angiogenic/progenitor cell mobilization
It is now clear that the mobilization of various angiogenic/
progenitor cells from the bone marrow to sites of ischemia is 
critical for neovascularization (Sieveking and Ng, 2009). Because 
the spleen serves as a reservoir for peripheral stem/progenitor 
cells (Heeschen et al., 2003), to further elucidate the mecha-
nisms of androgen-induced angiogenesis in hindlimb ischemia, 
the early mobilization of angiogenic/progenitor cells was as-
sessed in both the bone marrow and the spleen. Mononuclear 
cells (MNCs) staining positive for ulex lectin and uptake of Dil-
acetylated low density lipoprotein (AcLDL) represent a hetero-
geneous population of cells with angiogenic activity (Asahara 
et al., 1997). Although the precise role of these cells in angiogen-
esis has been debated, these cells have been reported to aug-
ment angiogenesis in a paracrine fashion through the secretion 
of various growth factors (Heil et al., 2004; Sieveking et al., 
2008). In females, estrogen has also been demonstrated to mo-
bilize bone marrow–derived angiogenic/progenitor cells that 
participate in cardiovascular regeneration (Iwakura et al., 2006). 
Similarly, the findings of this study show that androgens modu-
late the mobilization of angiogenic cells. Orchidectomy mark-
edly decreased the numbers of ulex+/AcLDL+ cells in the bone 
marrow (22.8 ± 1 vs. 13.4 ± 0.9 cells/200× field for control vs. 
orchidectomized mice, respectively; P < 0.001 using ANOVA; 
Fig. 6 A) and the spleen (20.6 ± 0.8 vs. 15.2 ± 0.7 cells/200× 
field for control vs. orchidectomized mice, respectively; P < 
0.001 using ANOVA; Fig. 6 B). DHT treatment rescued 
Figure 6.  Endogenous androgens modulate angiogenic/progenitor cell mobilization in response to ischemia. (A and B) Ulex+/AcLDL+ cells in the 
bone marrow (A) and spleen (B). Cells were seeded at a density of 5 × 106 cells/mm2 and after 4 d were assessed for the ability to ingest 4 µg/ml AcLDL 
(Invitrogen) and to bind 10 µg/ml FITC–UEA-1 (Sigma-Aldrich) via fluorescence microscopy. (C and D) SCA-1+/CXCR4+ cells in the bone marrow (C) and 
spleen (D). Hematopoietic progenitor cells were assessed using methylcellulose assays. (E and F) Granulocyte/macrophage CFUs in the bone marrow  
(E) and spleen (F). (G and H) Erythroid CFUs in the bone marrow (G) and spleen (H; n = 6/group; combined data from three independent experiments  
are shown). *, P < 0.05; **, P < 0.01; and ***, P < 0.001 using ANOVA. All data are expressed as means ± SEM.JEM VOL. 207, February 15, 2010  351
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Real-time RT-PCR. Real-time RT-PCR was performed in triplicate using 
iQ SYBR Green Supermix and the iCycler Real-Time PCR Detection System 
(Bio-Rad Laboratories). For the animal studies, the relative expression (R) of 
each target mRNA was calculated based on the Pfaffl equation (Pfaffl, 2001), 
as follows: R = (Etarget)∆Cttarget/(Ereference)∆Ctreference, where ∆Ct = Ctischemic  
Ctnonischemic. The reference was -actin or 2-microglobuin mRNA.
Animal studies. All animal studies were performed under ethical approvals 
of the Sydney South West Area Health Service Animal Welfare Commit-
tee. Male and female C57Bl6/J mice at 6 wk of age were randomized to or-
chidectomy, ovariectomy, or sham castration. 10 d later, castrated mice 
received a 1-cm subdermal silastic implant filled with crystalline DHT.
Matrigel plug implantation model. Matrigel plug assays were performed 
as  described  previously  (Passaniti  et  al.,  1992).  Commercially  available 
Matrigel (BD) without phenol red was supplemented with 100 ng/ml of 
basic fibroblast growth factor.
Hindlimb ischemia model. Hindlimb ischemia and subsequent perfusion 
(Moor Instruments) and monitoring was performed as described previously 
(Stabile et al., 2003).
Angiogenic/progenitor cell mobilization. For flow cytometric analysis 
(FC500; Beckman Coulter), MNCs were stained with PE-conjugated anti-
bodies against SCA-1 (BioLegend) and FITC-conjugated antibodies against 
CXCR4 (BD) with matched isotype controls. CFU assays for granulocyte/
macrophage and erythroid progenitors were set up in methylcellulose me-
dium (MethoCult; STEMCELL Technologies Inc.).
Statistical analysis. Data are expressed as means ± SEM. Comparisons be-
tween groups were performed using a two-tailed t test or by a one-way 
ANOVA with post hoc analyses for pairwise comparisons (Newman-Keuls 
multiple comparison). Prism software (version 4.00; GraphPad Software, Inc.) 
for Windows was used for statistical analysis.
Online supplemental material. Fig. S1 depicts a dose-dependent aug-
mentation of Matrigel-based tubulogenesis in male ECs exposed to DHT for 
24 h. In Fig. S2, we show differential gene expression of the AR in male and 
female ECs as well as female ECs transfected with an AR expression vector. 
Fig. S3 demonstrates the effect of castration and DHT treatment on the 
functional recovery of male mice subjected to femoral artery ligation. Fig. S4 
shows the expression of angiogenesis-related genes in response to hindlimb 
ischemia.  Online  supplemental  material  is  available  at  http://www.jem 
.org/cgi/content/full/jem.20091924/DC1.
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